EOLS Slumps On Stock Offering, BLCM CFO To Exit, NVRO Trims Revenue Outlook

Today’s Daily Dose brings you news about the resignation of Bellicum Pharma’s CFO; Evolus’ stock offering; Nevro’s preliminary revenue figures for the second quarter of 2018 and full year outlook; FDA clearance of Quidel’s new test and Spero’s BARDA funding.

Read on…

Bellicum Pharmaceuticals Inc.’s (BLCM) Chief Financial Officer, Alan Musso, will be leaving the Company effective August 31, 2018.

Rosemary Williams, Bellicum’s Vice President of Finance and Controller, will serve as the Company’s interim principal accounting officer.

The Company’s lead product candidate is BPX-501 under multiple phase 1/2 clinical trials in adults and pediatric patients with leukemias, lymphomas, and genetic blood diseases in the U.S. and Europe. Also in the pipeline are BPX-601, BPX-701, and CaspaCIDe-enabled CD19 CAR-T, all under phase I studies.

Near-term Catalysts:

— Top line data from the BPX-501 E.U. registration trial in malignant and nonmalignant pediatric patients undergoing haploidentical hematopoietic stem cell transplant is expected at the end of 2018.
— Interim analysis of a comparator trial of malignant and nonmalignant patients receiving a matched unrelated donor (MUD) HSCT is also expected this year.
— Initial findings from phase I clinical trials of BPX-601 in pancreatic cancer, BPX-701 in Acute myeloid leukemia/ Myelodysplastic syndromes, and CaspaCIDe-enabled CD19 CAR-T in pediatric acute lymphoblastic leukaemia (ALL) are expected to be reported later this year.

BLCM closed Monday’s trading at $7.97, down 1.48%.

Clearside Biomedical Inc. (CLSD) will be presenting data from its pivotal phase III trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveits, dubbed PEACHTREE, on Wednesday, July 25 at the 2018 American Society of Retina Specialists Annual Meeting.

Initial topline results from the PEACHTREE trial were reported on March 5, 2018, which sent the stock up as much as 69% that day.

According to the trial results reported in March, the trial met the primary endpoint – demonstrating statistically significant improvement in proportion of patients gaining 15 or more letters in visual acuity. All the secondary endpoints were also achieved in the trial.

CLSD closed Monday’s trading at $10.63, up 3.40%. In after-hours, the stock was up 11.01% at $11.80.

Shares of Evolus Inc. (EOLS) were down over 10% in extended trading on Monday, following its proposed public offering of common stock.

About 5 million shares of the common stock are to be sold in the offering – with 2.5 million shares to be offered by Evolus and 2.5 million shares to be offered by a selling stockholder of Evolus. In addition, Evolus and the selling stockholder are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 750,000 shares.

The Company is developing DWP-450 for the treatment of glabellar lines, also known as frown lines, in adult patients, a rival to Allergan’s (AGN) Botox.

In May of this year, the FDA rejected the Company’s Biologics License Application for DWP-450. There were deficiencies in items related to Chemistry, Manufacturing, and Controls (“CMC”) processes that led to the rejection. However, no deficiencies were related to clinical or non-clinical matters.

The Company expects to resubmit DWP-450 NDA to the FDA next month (August).

EOLS closed Monday’s trading at $25.13, down 3.97%. In after-hours, the stock fell 10.90% to $22.39.

Medical device company Nevro Corp. (NVRO) expects second quarter 2018 worldwide revenue to be approximately $96.1 million compared to $78.0 million in the second quarter of 2017.

Analysts polled by Thomson Reuters are expecting revenue of $96.29 million for the second quarter. The Company is slated to report Q2 results in the first week of August.

The Company now expects worldwide revenue for the full year 2018 to be in the range of $385.0 to $390.0 million, down from its prior expectations of $400.0 to $410.0 million range, as announced in May 2018.

The revised revenue forecast for full year 2018 also falls short of analysts’ consensus estimate of $393.37 million.

NVRO closed Monday’s trading at $58.71, up 1.63%.

Quidel Corp. (QDEL) has received FDA clearance to market its Solana Bordetella Complete Assay for the detection of pertussis.

Pertussis, or whooping cough, is a very contagious disease caused by the Bordetella pertussis bacteria.

QDEL closed Monday’s trading at $69.60, up 0.62%.

Spero Therapeutics Inc. (SPRO) has received funding of $15.7 million, with the potential for up to an additional $28.5 million over 5 years, from the Biomedical Advanced Research and Development Authority (BARDA), which will support the further clinical development of the Company’s investigational oral drug SPR994 for the treatment of complicated urinary tract infections (cUTIs).

A pivotal Phase 3 trial of SPR994 for the treatment of complicated urinary tract infections (cUTIs) caused by antibiotic resistant Gram-negative bacteria is on track to be initiated around year-end 2018.

SPRO closed Monday’s trading at $11.70, down 3.62%.

Tonix Pharmaceuticals Holding Corp.’s (TNXP) investigational new drug, TNX-102 SL, for the treatment of agitation in Alzheimer’s disease has been granted Fast Track designation by the FDA.

The Company received the go-ahead from the FDA as recently as April to initiate a phase II potential pivotal efficacy study of TNX-102 SL 5.6 mg in patients with agitation in Alzheimer’s disease.

The same drug, TNX-102 SL, or Tonmya, for the treatment of posttraumatic stress disorder (PTSD), has previously been designated as a Breakthrough Therapy by the FDA. It is currently in a Phase 3 study for military-related PTSD, with an interim analysis expected in the third quarter of 2018.

TNXP closed Monday’s trading at $4.18, up 5.82%.

by RTTNews Staff Writer

Source: Read Full Article